Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Hormone Research in Paediatrics

Volumn 76, Issue 2, 2011, Pages 73-85

  Reisch, Nicole ^a   Arlt, Wiebke ^a   Krone, Nils ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

21 Hydroxylase deficiency; Congenital adrenal hyperplasia; Fertility; Hypertension; Obesity; Osteoporosis

Indexed keywords

DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; PIOGLITAZONE; PREDNISOLONE;

ADRENALECTOMY; BEDTIME DOSAGE; BODY MASS; BONE DENSITY; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CONGENITAL ADRENAL HYPERPLASIA; CORTICOSTEROID THERAPY; DRUG DOSE TITRATION; EVENING DOSAGE; FEMALE SUBFERTILITY; HORMONE SUBSTITUTION; HUMAN; MALE INFERTILITY; MORNING DOSAGE; OSTEOPENIA; OSTEOPOROSIS; PREGNANCY RATE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOCIAL PSYCHOLOGY; STEROID 21 MONOOXYGENASE DEFICIENCY; WEIGHT GAIN; WELLBEING;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; AGED; BODY MASS INDEX; BONE DENSITY; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; GROWTH; HUMANS; HYDROCORTISONE; INFERTILITY; INSULIN RESISTANCE; MALE; MIDDLE AGED; MINERALOCORTICOIDS; PATIENT CARE PLANNING; PREGNANCY; PREGNANCY RATE; QUALITY OF LIFE; STEROID 21-HYDROXYLASE;

EID: 84860401478     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000327794     Document Type: Review

References (91)

1. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291.
2. Merke DP, Bornstein SR: Congenital adrenal hyperplasia. Lancet 2005; 365: 2125-2136.
3. Krone N, Dhir V, Ivison HE, Arlt W: Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf) 2007; 66: 162-172.
4. Arlt W, Krone N: Adult consequences of congenital adrenal hyperplasia. Horm Res 2007; 68: 158-164.
5. Nimkarn S, Lin-Su K, Berglind N, Wilson RC, New MI: Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92: 137-142.
6. Clayton PE, Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW: Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002; 58: 188-195.
7. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 4133-4160.
8. Stikkelbroeck NMML, van't Hof-Grootenboer BAE, Hermus ARMM, Otten BJ, van't Hof MA: Growth Inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: In early infancy and (pre)puberty. J Clin Endocrinol Metab 2003; 88: 3525-3530.
9. Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP: Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: An evidencebased recommendation. J Clin Endocrinol Metab 2009; 94: 3882-3888.
10. Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP: Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: Deceleration of growth velocity during puberty. J Clin Endocrinol Metab 2007; 92: 1635-1639.
11. Claahsen-Van Der Grinten HL, Noordam K, Borm GF, Otten BJ: Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 1205-1209.
12. Arlt W, Allolio B: Adrenal insufficiency. Lancet 2003; 361: 1881-1893.
13. Riepe FG, Krone N, Viemann M, Partsch CJ, Sippell WG: Management of congenital adrenal hyperplasia: Results of the ESPE questionnaire. Horm Res 2002; 58: 196-205.
14. German A, Suraiya S, Tenenbaum-Rakover Y, Koren I, Pillar G, Hochberg Z: Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. J Clin Endocrinol Metab 2008; 93: 4707-4710.
15. Debono M, Ross RJ, Newell-Price J: Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009; 160: 719-729.
16. Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ: Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006; 65: 45-50.
17. Bryan SM, Honour JW, Hindmarsh PC: Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. J Clin Endocrinol Metab 2009; 94: 3477-3480.
18. Verma S, Vanryzin C, Sinaii N, Kim MS, Nieman LK, Ravindran S, Calis KA, Arlt W, Ross RJ, Merke DP: A pharmacokinetic and pharmacodynamic study of delayed- and extended- release hydrocortisone (Chronocort) versus conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010; 72: 441-447.
19. Martinerie L, Pussard E, Foix-L'Helias L, Petit F, Cosson C, Boileau P, Lombes M: Physiological partial aldosterone resistance in human newborns. Pediatr Res 2009; 66: 323-328.
20. Hindmarsh PC: Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 193-208.
21. Cameron FJ, Kaymakci B, Byrt EA, Ebeling PR, Warne GL, Wark JD: Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1995; 80: 2238-2243.
22. Mora S, Saggion F, Russo G, Weber G, Bellini A, Prinster C, Chiumello G: Bone density in young patients with congenital adrenal hyperplasia. Bone 1996; 18: 337-340.
23. Jääskelainen J, Voutilainen R: Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1996; 45: 707-713.
24. Guo CY, Weetman AP, Eastell R: Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1996; 45: 535-541.
25. Hagenfeldt K, Martin Ritzen E, Ringertz H, Helleday J, Carlstrom K: Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur J Endocrinol 2000; 143: 667-671.
26. Paganini C, Radetti G, Livieri C, Braga V, Migliavacca D, Adami S: Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res 2000; 54: 164-168.
27. Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, Hermus AR, Otten BJ: Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88: 1036-1042.
28. Christiansen P, Molgaard C, Muller J: Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2004; 61: 133-136.
29. King JA, Wisniewski AB, Bankowski BJ, Carson KA, Zacur HA, Migeon CJ: Longterm corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 865-869.
30. Falhammar H, Filipsson H, Holmdahl G, Janson P-O, Nordenskjold A, Hagenfeldt K, Thoren M: Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 4643-4649.
31. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ: Health status of adults with congenital adrenal hyperplasia: A cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95: 5110-5121.
32. Sciannamblo M, Russo G, Cuccato D, Chiumello G, Mora S: Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4453-4458.
33. Bachelot A, Plu-Bureau G, Thibaud E, Laborde K, Pinto G, Samara D, Nihoul-Fekete C, Kuttenn F, Polak M, Touraine P: Longterm outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2007; 67: 268-276.
34. Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, Christin- Maitre S, Bouvattier C, Raux-Demay MC, Bouchard P, Carel JC, Leger J, Kuttenn F, Polak M, Touraine P: Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2008; 158: 879-887.
35. Völkl TM, Simm D, Beier C, Dorr HG: Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 2006; 117:e98-e105.
36. Völkl TMK, Simm D, Dotsch J, Rascher W, Dorr HG: Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4888-4895.
37. Cornean RE, Hindmarsh PC, Brook CG: Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998; 78: 261-263.
38. Williams RM, Deeb A, Ong KK, Bich W, Murgatroyd PR, Hughes IA, Acerini CL: Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2010; 72: 155-160.
39. Falhammar H, Filipsson H, Holmdahl G, Janson P-O, Nordenskjold A, Hagenfeldt K, Thoren M: Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 110-116.
40. Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP: Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: Potential clinical implications. J Clin Endocrinol Metab 2002; 87: 2114-2120.
41. Saygili F, Oge A, Yilmaz C: Hyperinsulinemia and insulin insensitivity in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: The relationship between serum leptin levels and chronic hyperinsulinemia. Horm Res 2005; 63: 270-274.
42. Völkl TM, Simm D, Korner A, Rascher W, Kiess W, Kratzsch J, Dorr HG: Does an altered leptin axis play a role in obesity among children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency? Eur J Endocrinol 2009; 160: 239-247.
43. Roche EF, Charmandari E, Dattani MT, Hindmarsh PC: Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): A preliminary report. Clin Endocrinol 2003; 58: 589-596.
44. de Silva KS, Kanumakala S, Brown JJ, Jones CL, Warne GL: 24-hour ambulatory blood pressure profile in patients with congenital adrenal hyperplasia-a preliminary report. J Pediatr Endocrinol Metab 2004; 17: 1089-1095.
45. Mooij CF, Kapusta L, Otten BJ, Claahsenvan der Grinten HL: Blood pressure in the first year of life in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A pilot study. Horm Res Paediatr 2010; 74: 328-332.
46. Botero D, Arango A, Danon M, Lifshitz F: Lipid profile in congenital adrenal hyperplasia. Metabolism 2000; 49: 790-793.
47. Sartorato P, Zulian E, Benedini S, Mariniello B, Schiavi F, Bilora F, Pozzan G, Greggio N, Pagnan A, Mantero F, Scaroni C: Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 1015-1018.
48. Bayraktar F, Dereli D, Ozgen AG, Yilmaz C: Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J 2004; 51: 601-608.
49. Zimmermann A, Grigorescu-Sido P, Al- Khzouz C, Patberg K, Bucerzan S, Schulze E, Zimmermann T, Rossmann H, Geiss HC, Lackner KJ, Weber MM: Alterations in lipid and carbohydrate metabolism in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr 2010; 74: 41-49.
50. Paula FJ, Gouveia LM, Paccola GM, Piccinato CE, Moreira AC, Foss MC: Androgenrelated effects on peripheral glucose metabolism in women with congenital adrenal hyperplasia. Horm Metab Res 1994; 26: 552-556.
51. Kroese JM, Mooij CF, van der Graaf M, Hermus AR, Tack CJ: Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. Eur J Endocrinol 2009; 161: 887-894.
52. Mulaikal RM, Migeon CJ, Rock JA: Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987; 316: 178-182.
53. Krone N, Wachter I, Stefanidou M, Roscher AA, Schwarz HP: Mothers with congenital adrenal hyperplasia and their children: Outcome of pregnancy, birth and childhood. Clin Endocrinol (Oxf) 2001; 55: 523-529.
54. Hoepffner W, Schulze E, Bennek J, Keller E, Willgerodt H: Pregnancies in patients with congenital adrenal hyperplasia with complete or almost complete impairment of 21-hydroxylase activity. Fertil Steril 2004; 81: 1314-1321.
55. Jääskelainen J, Hippelainen M, Kiekara O, Voutilainen R: Child rate, pregnancy outcome and ovarian function in females with classical 21-hydroxylase deficiency. Acta Obstet Gynecol Scand 2000; 79: 687-692.
56. Casteras A, De Silva P, Rumsby G, Conway GS: Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): Normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 2009; 70: 833-837.
57. Holmes-Walker DJ, Conway GS, Honour JW, Rumsby G, Jacobs HS: Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1995; 43: 291-296.
58. Ogilvie CM, Rumsby G, Kurzawinski T, Conway GS: Outcome of bilateral adrenalectomy in congenital adrenal hyperplasia: One unit's experience. Eur J Endocrinol 2006; 154: 405-408.
59. Moran C, Azziz R, Weintrob N, Witchel SF, Rohmer V, Dewailly D, Marcondes JAM, Pugeat M, Speiser PW, Pignatelli D, Mendonca BB, Bachega TAS, Escobar-Morreale HF, Carmina E, Fruzzetti F, Kelestimur F: Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 3451-3456.
60. Bidet M, Bellanne-Chantelot C, Galand- Portier MB, Golmard JL, Tardy V, Morel Y, Clauin S, Coussieu C, Boudou P, Mowzowicz I, Bachelot A, Touraine P, Kuttenn F: Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95: 1182-1190.
61. Meyer-Bahlburg HF, Dolezal C, Baker SW, New MI: Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008; 37: 85-99.
62. Jääskelainen J, Kiekara O, Hippelainen M, Voutilainen R: Pituitary gonadal axis and child rate in males with classical 21-hydroxylase deficiency. J Endocrinol Invest 2000; 23: 23-27.
63. Cabrera MS, Vogiatzi MG, New MI: Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 3070-3078.
64. Stikkelbroeck NMML, Otten BJ, Pasic A, Jager GJ, Sweep CGJF, Noordam K, Hermus ARMM: High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 5721-5728.
65. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, Wolff H, Schwarz H-P, Quinkler M, Beuschlein F, Reincke M: High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009; 94: 1665-1670.
66. Martinez-Aguayo A, Rocha A, Rojas N, Garcia C, Parra R, Lagos M, Valdivia L, Poggi H, Cattani A, Chilean Collaborative Testicular Adrenal Rest Tumor Study Group: Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92: 4583-4589.
67. Claahsen-Van Der Grinten HL, Sweep FC, Blickman JG, Hermus AR, Otten BJ: Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007; 157: 339-344.
68. Stikkelbroeck NM, Hermus AR, Schouten D, Suliman HM, Jager GJ, Braat DD, Otten BJ: Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: Results of ultrasonography and MR imaging. Eur Radiol 2004; 14: 1802-1806.
69. Claahsen-Van Der Grinten HL, Hulsbergenvan de Kaa CA, Otten BJ: Ovarian adrenal rest tissue in congenital adrenal hyperplasia-a patient report. J Pediatr Endocrinol Metab 2006; 19: 177-182.
70. Claahsen-Van Der Grinten HL, Otten BJ, Stikkelbroeck MM, Sweep FC, Hermus AR: Testicular adrenal rest tumours in congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 209-220.
71. Reisch N, Scherr M, Flade L, Bidlingmaier M, Schwarz HP, Muller-Lisse U, Reincke M, Quinkler M, Beuschlein F: Total adrenal volume but not testicular adrenal rest tumor volume is associated with hormonal control in patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95: 2065-2072.
72. Claahsen-Van Der Grinten HL, Otten BJ, Sweep FC, Hermus AR: Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil Steril 2007; 88: 705.e5-705.e8.
73. Claahsen-Van Der Grinten HL, Otten BJ, Takahashi S, Meuleman EJH, Hulsbergenvan de Kaa C, Sweep FCGJ, Hermus ARMM: Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: Evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. J Clin Endocrinol Metab 2007; 92: 612-615.
74. Nordenskjold A, Holmdahl G, Frisen L, Falhammar H, Filipsson H, Thoren M, Janson PO, Hagenfeldt K: Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008; 93: 380-386.
75. Kuhnle U, Bullinger M, Schwarz HP: The quality of life in adult female patients with congenital adrenal hyperplasia: A comprehensive study of the impact of genital malformations and chronic disease on female patients life. Eur J Pediatr 1995; 154: 708-716.
76. Jääskelainen J, Voutilainen R: Long-term outcome of classical 21-hydroxylase deficiency: Diagnosis, complications and quality of life. Acta Paediatr 2000; 89: 183-187.
77. Berenbaum SA, Korman Bryk K, Duck SC, Resnick SM: Psychological adjustment in children and adults with congenital adrenal hyperplasia. J Pediatr 2004; 144: 741-746.
78. Frisen L, Nordenstrom A, Falhammar H, Filipsson H, Holmdahl G, Janson PO, Thoren M, Hagenfeldt K, Moller A, Nordenskjold A: Gender role behavior, sexuality, and psychosocial adaptation in women with congenital adrenal hyperplasia due to CYP21A2 deficiency. J Clin Endocrinol Metab 2009; 94: 3432-3439.
79. Nermoen I, Husebye E, Svartberg J, Lovas K: Subjective health status in men and women with congenital adrenal hyperplasia: A population- based survey in Norway. Eur J Endocrinol 2010; 163: 453-459.
80. Reisch N, Hahner S, Bleicken B, Flade L, Gil FP, Loeffler M, Ventz M, Hinz A, Beuschlein F, Allolio B, Reincke M, Quinkler M: Quality of life is less impaired in adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency than in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf) 2011; 74: 166-173.
81. Girgis R, Winter JS: The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997; 82: 3926-3929.
82. Gussinye M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibanez L, Yeste D: Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 1997; 100: 671-674.
83. de Almeida Freire PO, de Lemos-Marini SH, Maciel-Guerra AT, Morcillo AM, Matias Baptista MT, de Mello MP, Guerra G Jr: Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A cross-sectional study of factors involved in bone mineral density. J Bone Miner Metab 2003; 21: 396-401.
84. Elnecave RH, Kopacek C, Rigatto M, Keller Brenner J, Sisson de Castro JA: Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency. J Pediatr Endocrinol Metab 2008; 21: 1155-1162.
85. Speiser PW, Serrat J, New MI, Gertner JM: Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 75: 1421-1424.
86. Hoepffner W, Herrmann A, Willgerodt H, Keller E: Blood pressure in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2006; 19: 705-711.
87. Nebesio TD, Eugster EA: Observation of hypertension in children with 21-hydroxylase deficiency: A preliminary report. Endocrine 2006; 30: 279-282.
88. Völkl TMK, Simm D, Korner A, Kiess W, Kratzsch J, Dorr HG: Adiponectin levels are high in children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Acta Paediatr 2009; 98: 885-891.
89. Hagenfeldt K, Janson PO, Holmdahl G, Falhammar H, Filipsson H, Frisen L, Thoren M, Nordenskjold A: Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23: 1607-1613.
90. Johannsen TH, Ripa CPL, Mortensen EL, Main KM: Quality of life in 70 women with disorders of sex development. Eur J Endocrinol 2006; 155: 877-885.
91. Urban MD, Lee PA, Migeon CJ: Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978;299:1392-1396.